Fluid Resuscitation Strategy for Acute Pancreatitis Based on the WATERFALL Trial
Use moderate fluid resuscitation with lactated Ringer's solution rather than aggressive fluid resuscitation in patients with acute pancreatitis. The WATERFALL trial definitively demonstrated that aggressive early fluid resuscitation increases fluid overload without improving clinical outcomes 1.
Key Findings from the WATERFALL Trial
The WATERFALL trial was halted early after enrolling 249 patients due to safety concerns 1:
- No benefit in disease severity: Moderately severe or severe pancreatitis occurred in 22.1% with aggressive resuscitation versus 17.3% with moderate resuscitation (no significant difference) 1
- Significant harm from aggressive resuscitation: Fluid overload developed in 20.5% of aggressively resuscitated patients versus only 6.3% with moderate resuscitation (adjusted relative risk 2.85,95% CI 1.36-5.94, P=0.004) 1
- Longer hospitalizations: Median hospital stay was 6 days with aggressive resuscitation versus 5 days with moderate resuscitation 1
Recommended Fluid Resuscitation Protocol
Moderate Resuscitation Strategy (Preferred)
Initial bolus 1:
- 10 ml/kg if patient has hypovolemia
- No bolus if patient is normovolemic
Maintenance rate 1:
- 1.5 ml/kg/hour for all patients
Reassessment schedule: Evaluate at 12,24,48, and 72 hours and adjust based on clinical status 1
Aggressive Strategy (NOT Recommended)
For comparison, the aggressive protocol that caused harm consisted of 1:
- Initial bolus: 20 ml/kg
- Maintenance: 3 ml/kg/hour
Fluid Type Selection
Lactated Ringer's solution is the preferred crystalloid 2, 3. While the 2018 AGA guidelines made no recommendation between normal saline and Ringer's lactate 2, subsequent evidence supports Ringer's lactate for 3:
- Reducing SIRS
- Decreasing organ failure
- Reducing ICU length of stay
- Potential anti-inflammatory effects 2
Avoid hydroxyethyl starch (HES) fluids, which increase multiple organ failure (OR 3.86,95% CI 1.24-12.04) without mortality benefit 2.
Goal-Directed Therapy Framework
The 2018 AGA guidelines suggest goal-directed therapy for fluid management (conditional recommendation, very low quality evidence) 2. The 2019 WSES guidelines emphasize 2:
Monitoring parameters:
- Hematocrit
- Blood urea nitrogen
- Creatinine
- Lactate levels
- Continuous vital signs if organ dysfunction occurs
Key principle: Frequent reassessment is essential since fluid overload has detrimental effects 2. The WATERFALL trial validates this concern by demonstrating nearly 3-fold increased risk of fluid overload with aggressive protocols 1.
Clinical Implementation
Adjust fluid therapy based on 2:
- Patient's age
- Body weight
- Pre-existing renal conditions
- Pre-existing cardiac conditions
- Hemodynamic status on serial assessments
Common Pitfalls to Avoid
Do not assume "more is better" with fluids - The WATERFALL trial definitively refutes the widespread practice of aggressive early hydration 1, 4. This represents a major paradigm shift in acute pancreatitis management 4.
Avoid fluid overload, which causes 1:
- Respiratory complications
- Acute kidney injury
- Prolonged hospitalization
- No improvement in pancreatitis severity
Do not use colloids routinely - They are associated with renal impairment and coagulopathy 3.